Results 51 to 60 of about 1,577 (196)

Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma

, 2010
Glioblastoma patients are still not cured by the treatments available at the moment. We investigated the therapeutic properties of temozolomide in combination with F16-IL2, a clinical-stage immunocytokine consisting of human interleukin (IL)-2 fused to ...
Pedretti, Marta, M Pedretti, D. Neri, L. Bello, Bello, Lorenzo, J. Mårlind, C Verpelli, Bertani, G., Neri, Dario; id_orcid, G Bertani, Verpelli, Chiara, Mårlind, Jessica, C. Verpelli, C. Sala, Sala, Carlo, J Mårlind, D Neri, M. Pedretti, C Sala, L Bello, G. Bertani, Bertani G, Bello L, Pedretti M, Mårlind J, Neri D, Sala C, Verpelli C   +27 more
core   +1 more source

Interleukin‐12: Central Roles in Immune Regulation and Disease Therapy

Immunology &Cell Biology, Volume 104, Issue 10, Page 996-1014, November‐December 2026.
IL‐12 levels are tightly regulated to balance effective protective immunity against infections and cancer with the risk of excessive inflammation and autoimmune disease. Both insufficient and excessive IL‐12 activity can therefore be detrimental, highlighting the importance of precisely controlling its production and signaling. ABSTRACT Interleukin‐12 (
Anthi Psoma, Geert van den Bogaart
wiley   +1 more source

CLEC12A-directed immunocytokine with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia. [PDF]

Front Immunol
Despite recent advancements, acute myeloid leukemia (AML) remains a therapeutic challenge. While monoclonal antibodies (mAbs) leveraging natural killer (NK) cells through antibody-dependent cellular cytotoxicity show great potential, none have gained ...
Klimovich B, Anton L, Jung J, Lim Y, Lee B, Won J, Zekri L, Chashchina A, Pflügler M, Heitmann JS, Jung G, Salih HR.   +11 more
europepmc   +2 more sources

Supplementary Figure 1 from A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity

, 2011
Supplementary Figure 1 from A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor ...
Thore Hettmann (8294829), Stefan O. Mueller (14981906), Yan Lan (314079), Beatrice Brunkhorst (757924), Yaping Sun (168299), Kin-Ming Lo (14981909), Stephen D. Gillies (9162113)   +6 more
core   +1 more source

An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity [PDF]

, 2010
Classical Hodgkin’s lymphoma is one of the most curable cancers today. However, non-responders, tumour relapses and long-term toxicities of the treatment make it necessary to look for alternative drugs.
Zuther, Martin
core   +1 more source

A Multimodal Framework to Guide Solid Tumor Indications for Natural Killer Cell‐Based Therapy

European Journal of Immunology, Volume 56, Issue 9, September 2026.
This study integrates immunohistochemical evidence of NK cell infiltration in solid tumors, clinical outcomes of NK cell‐based therapies, and transcriptomic analyses of more than 10,000 TCGA samples. Together, these complementary datasets provide a multimodal framework for prioritizing tumor indications and informing the rational design of future NK ...
L. Chiossone, V. Picant, Q. Barbier, T. A. Fehniger, Eric Vivier   +4 more
wiley   +1 more source

Tissue‐Resident Macrophage in Inflammation and Cancer

MedComm, Volume 7, Issue 9, September 2026.
Opposing macrophage functions in inflammation and cancer converge on shared mechanistic nodes, informing cross‐disease therapeutic strategies. ABSTRACT Tissue‐resident macrophages (TRMs) are long‐lived immune cells strategically distributed across organs, where their functional plasticity enables both homeostatic maintenance and pathological ...
Siyuan Huang, Jiangbo Fan, Wenyi Liu, Di Liu, Rui Wang, Yuanyang Wang, Jianhui Sun, Huacai Zhang, Qingli Cai, Zhe Xu, Fang Xu, Jianxin Jiang, Zhen Wang, Ling Zeng   +13 more
wiley   +1 more source

Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment

Immunology &Cell Biology, Volume 104, Issue 7, Page 711-728, August 2026.
Three interconnected processes in glioblastoma (GBM) biology: initiation, stratification, and immunosuppression. 1) Initiation: GBM initiation is proposed to occur through migration of TERT mutation‐bearing neural stem cells from the subventricular zone to the frontal and temporal cortices, where a subsequent oncogenic transformation drives their ...
Emerson Achari, Farah Ahmady‐Nield, Amit Sharma, Ingo G. H. Schmidt‐Wolf, Jarek Maciaczyk, Rodney B. Luwor, Adrian A. Achuthan   +6 more
wiley   +1 more source

Table_1_Antibody landscape of C57BL/6 mice cured of B78 melanoma via a combined radiation and immunocytokine immunotherapy regimen.xlsx

, 2023
Sera of immune mice that were previously cured of their melanoma through a combined radiation and immunocytokine immunotherapy regimen consisting of 12 Gy of external beam radiation and the intratumoral administration of an immunocytokine (anti-GD2 mAb ...
Kaitlin Tetreault (17436324), Jacquelyn Ann Hank (17436333), Richard S. Pinapati (6013865), Arika S. Feils (11702552), Drew Melby (17436321), Nicholas Mathers (5135147), Trang Le (274049), Paul Mark Sondel (17436339), Kyungmann Kim (17436327), Mackenzie Heck (15174509), Bradley H. Garcia (17436330), Zachary Scott Morris (17436336), Angie Xu (17436318), Irene M. Ong (8353449), Jigar Patel (269773), Noah Tsarovsky (15174500), Anna Hoefges (6468203), Amy K. Erbe (9162116), Sean J. McIlwain (3221448)   +18 more
core   +1 more source

Immunocytokines in cancer: a safety perspective [PDF]

Front Immunol
Immunocytokines (ICs) are engineered biologics comprising a fusion of cytokines to antibodies, designed to deliver targeted cytokines to diseased tissues and mitigate the severe safety challenges associated with systemic cytokine therapy. A rapidly growing number of clinical trials have evaluated ICs, largely based on IL-2, IL-12, and TNF-α, across ...
Prajapati K, Betts C, Stebbings R.
europepmc   +2 more sources